ClinicalTrials.gg
Active, not recruitingNCT05630209Updated Apr 17, 2026

Blood Brain Barrier (BBB) Disruption Using Exablate Focused Ultrasound With Doxorubicin for Treatment of Pediatric Diffuse Intrinsic Pontine Gliomas (DIPG)

A Phase 1/2 interventional study of Exablate and Doxorubicin in Brain Tumor, sponsored by InSightec. Active, not recruiting at 3 sites in United States. Open to participants aged 5 Years to 21 Years. Per ClinicalTrials.gov, last updated 2026-04-17.

Sponsored by InSightec · Phase 1/2, Interventional, and Device feasibility

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as active, not recruiting.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
5 Years to 21 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 1,443 studies in Brain Neoplasms with a site in United States — 230 open to participants now, 351 under way, 18 of them phase 3. Brain Neoplasms · United States.

Planned enrollment
926th of 1,188
10 · median 30
Started
2023
with 50 others
Phase 1/2
136 of 1,443
20 open now
Primary completion
2026-06
later than 43 of 349 live
Registered
1,265th of 1,443
by date

Among the 1,443 studies in Brain Neoplasms with a site in United States, this one is the 926th largest by planned enrollment of the 1,188 interventional ones that give a count, is one of 51 that started in 2023, is one of 136 in phase 1/2, reaches primary completion later than 43 of the 349 other live ones, and was the 1,265th registered.

Brain Neoplasms

2,441 studies on the registry are indexed under Brain Neoplasms; 541 are open to participants now.

Browse Brain Neoplasms studies →

Open to participants now

230 of the 1,443 studies in Brain Neoplasms with a site in United States are open now. Recruiting first, the newest first:

225 more — sign in →

All 230 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 425 Brain Neoplasms studies recruiting now, 286 (67%) set no upper age limit and 82 (19%) stop at 75 or younger; 80 take children under 18; 36 take healthy volunteers.

This study: 5 Years to 21 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,443 studies in Brain Neoplasms with a site in United States, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the safety and efficacy of targeted blood brain barrier disruption with Exablate Model 4000 Type2.0/2.1 in combination with Doxorubicin therapy for the treatment of DIPG in pediatric patients

Read the detailed description

This is a prospective, single arm, non-randomized feasibility study to evaluate the safety, feasibility and preliminary efficacy of Blood Brain Barrier Disruption (BBBD) using the Exablate Type 2 system in pediatric patients with Diffuse Intrinsic Pontine Gliomas (DIPG) undergoing Doxorubicin chemotherapy. The study will be conducted at up to three sites in the United States. Patients will undergo 3 treatment cycles, approximately 4-6 weeks apart. The study aims to establish feasibility and safety of Exablate BBBD in conjunction with Doxorubicin in the treatment of pediatric DIPG and assess preliminary efficacy in this patient population.

03

Conditions studied

  • Brain Tumor

Browse trials for

Keywords

  • DIPG
  • Focused Ultrasound
  • Chemotherapy
  • Phase I trial
  • Pediatrics
04

Who can participate

Ages eligible
5 Years to 21 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 5 and 21 years, inclusive. Subjects younger than 5 years old may be eligible after discussion with the Sponsor Medical Monitor/designee (i.e. DSMB).
  • Patient diagnosed with DIPG
  • At least 4-week and not greater than 12 weeks from completion of radiation therapy
  • Post-radiation imaging does not show evidence of necrosis/ hemorrhage or other features that contraindicate MRgFUS
  • If brain surgery occurred, at least 14 days passed since last brain surgery and the patient is fully recovered and neurologically stable
  • If on , stable or decreasing dose for at least 7 days prior to study entry
  • Stable or improving neurologic status for 7 days prior to study entry
  • Able and willing to give consent and/or assent or have a legal guardian who is able and willing to do so
  • Able to attend all study visits and with of at least 6 months

Exclusion criteria

Exclusion Criteria:

  • Tumor not visible on any pre-therapy or post-radiation imaging
  • Previous participation in other chemotherapy, molecularly targeted therapy, or immunotherapy treatment-related phase 1 or 2 trials
  • Symptoms and signs of increased intracranial pressure
  • Subject with disease
  • Subject with ventricular peritoneal shunt
  • Subject receiving bevacizumab (Avastin) therapy or increasing doses of
  • Anti-coagulant therapy, or medications known to increase risk of hemorrhage, (e.g., ASA, non-steroidal anti-inflammatory drugs [NSAIDs], statins) within prior to treatment
  • History of a bleeding disorder, coagulopathy or with a history of spontaneous tumor hemorrhage.
  • Hypertension per age
  • Cerebral or systemic vasculopathy, including intracranial thrombosis, vascular malformation, cerebral aneurysm, or vasculitis
  • (corticosteroids to prevent/treat brain edema are permitted).
  • Patients with positive status
  • Active seizure disorder or epilepsy (seizures despite medical treatment) for a minimum of 4 weeks prior to first cycle/Exablate BBBD procedure captured by history
  • Known sensitivity to gadolinium-based contrast agents
  • Known sensitivity to DEFINITY® ultrasound contrast agent or known to perflutren microsphere or its components, e.g., polyethylene glycol
  • to Doxorubicin
  • Previous treatment with complete cumulative doses of Doxorubicin, daunorubicin, idarubicin, and/or other anthracyclines and anthracenediones
  • Severely impaired renal function with estimated \<2 standard deviations for age
  • Patients that may require trastuzumab during the study
  • Patients that may require inhibitors and inducers of , CYP2D6, and/or P-gp during the study
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Experimental
    Blood Brain Barrier Disruption (BBBD)

    Exablate MR Guided Focused Ultrasound for Blood Brain Barrier Disruption with Doxorubicin for treating pediatric patients with DIPG

    Device: Exablate · Drug: Doxorubicin

Interventions

  • DeviceExablate

    Blood Brain Barrier Disruption (BBBD) via Exablate Type 2 system with microbubble resonators on the day of Doxorubicin infusion to treat DIPG brain tumors

    Also known as: Exablate BBBD

  • Doxorubicin infusion

    Also known as: Adriamycin, Rubex

06

What researchers measure

Primary outcomes

  1. Adverse Events

    All adverse events from first treatment to end of study will be documented and reported according to the CTCAE terminology and severity scale

    Time frame: 2 years

Secondary outcomes

  1. Blood Brain Barrier Disruption (BBBD)

    BBBD will be assessed as a comparative ratio measured in pre and post-sonication contrast-enhanced MR images

    Time frame: immediately post BBBD sonication

Other outcomes

  1. Progression Free Survival (PFS)

    PFS will be assessed based on the Response Assessment in Pediatric Neuro-Oncology (RAPNO) scale.

    Time frame: 2 years

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2023 (actual). Primary completion is estimated for Jun 2026, 41 months after the start.

Of 72 phase 1/2 interventional studies under Brain Neoplasms, half reached primary completion within 82 months of starting (the median), counting those still running; a quarter within 48 and three quarters within 105. This study's planned 41 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 18, 2022
First posted
Nov 29, 2022
StartActual
Jan 4, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Oct 2026
Last update
Apr 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05630209
Lead sponsor
InSightec
Responsible party
Sponsor
First posted
Nov 29, 2022
Start date
Jan 4, 2023
Primary completion
Jun 2026 (estimated)
Completion
Oct 2026 (estimated)
Last update
Apr 17, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Apr 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Doxorubicin

Start the discussion